Letter: Beta-Blockers and Myasthenia Gravis
Overview
Authors
Affiliations
Di Stefano V, Iacono S, Militello M, Leone O, Rispoli M, Ferri L Neurol Sci. 2024; 45(7):3481-3494.
PMID: 38383750 PMC: 11176220. DOI: 10.1007/s10072-024-07368-0.
Evaluation of Medication Exposure on Exacerbation of Disease in Patients With Myasthenia Gravis.
Petrucelli N, Barra M, Koehl J Neurohospitalist. 2024; 14(1):52-57.
PMID: 38235027 PMC: 10790617. DOI: 10.1177/19418744231206256.
Vanoli F, Mantegazza R Neurotherapeutics. 2022; 19(3):897-910.
PMID: 35165857 PMC: 9294078. DOI: 10.1007/s13311-022-01181-3.
Drugs That Induce or Cause Deterioration of Myasthenia Gravis: An Update.
Sheikh S, Alvi U, Soliven B, Rezania K J Clin Med. 2021; 10(7).
PMID: 33917535 PMC: 8038781. DOI: 10.3390/jcm10071537.
Mallikarjuna S, Velayutham S, Sowmini P, Jeyaraj M, Arunan S J Neurosci Rural Pract. 2019; 10(1):136-138.
PMID: 30765989 PMC: 6337967. DOI: 10.4103/jnrp.jnrp_150_18.